The effect of prostate-specific antigen screening during the last decade: Development of clinicopathological variables independently of the biopsy core number

BJU International

Volumn 106, Issue 9, 2010, Pages 1293-1297

  Ploussard, Guillaume ^a   Azancot, Vidal ^a   Nicolaiew, Nathalie ^a   Xylinas, Evanguelos ^a   Salomon, Laurent ^a   Allory, Yves ^a   Vordos, Dimitri ^a   Hoznek, Andras ^a   Abbou, Claude Clément ^a   De La Taille, Alexandre ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

biopsy scheme; prostate cancer; screening; stage migration

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; SEMINAL VESICLE;

ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 78349276976     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09361.x     Document Type: Article

References (23)

1. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78
2. Paquette EL, Sun L, Paquette LR, Connelly R, Mcleod DG, Moul JW,. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002; 60: 756-9
3. Moore AL, Dimitropoulou P, Lane A, et al. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int 2009; 104: 1592-8
4. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ,. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 2006; 67: 343-8
5. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H,. Stage migration in clinically localized prostate cancer. Eur Urol 2000; 38: 74-8
6. Desireddi NV, Roehl KA, Loeb S, et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007; 70: 950-5
7. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV., Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175: 907-12
8. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS,. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999; 17: 3167-72
9. Dong F, Reuther AM, Magi-Galluzzi C, Zhou M, Kupelian PA, Klein EA., Pathologic stage migration has slowed in the late PSA era. Urology 2007; 70: 839-42
10. Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008; 101: 1513-8
11. Singh H, Canto EI, Shariat SF, et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 2004; 171: 1089-92
12. De La Taille A, Antiphon P, Salomon L, et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003; 61: 1181-6
13. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW,. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003; 169: 125-9
14. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F,. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: 1309-22
15. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR,. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol 2005; 174: 1789-93
16. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC,. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416-9
17. Ploussard G, Xylinas E, Salomon L, et al. The Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance. Eur Urol 2009; 56: 891-8
18. Campos-Fernandes JL, Bastien L, Nicolaiew N, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009; 55: 600-6
19. Soulié M, Rebillard X, Villers A,. Prostate cancer screening. Prog Urol 2003; 13: 1272-5
20. Guy L, Van De Steene E, Védrine N, Teissonnière M, Boiteux JP,. General practical survey of individual prostate cancer screening. Prog Urol 2008; 18: 46-52
21. Pierorazio PM, Kinnaman MD, Wosnitzer MS, Benson MC, McKiernan JM, Goluboff ET., Prostate volume and pathologic prostate cancer outcomes after radical prostatectomy. Urology 2007; 70: 696-701
22. Yadav R, Tu JJ, Jhaveri J, Leung RA, Rao S, Tewari AK,. Prostate volume and the incidence of extraprostatic extension: is there a relation? J Endourol 2009; 23: 383-6
23. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8